Blood Glucose Monitoring System Market Size, Share, Industry Overview, Forecast 2032
Blood Glucose Monitoring System Market Size, Share, Industry Overview, Forecast 2032
The Blood Glucose Monitoring System Market comprises medical devices used to measure and track blood sugar levels in individuals with diabetes, playing a crucial role in effective disease management and prevention of complications. The market includes Self-Monitoring Blood Glucose (SMBG) systems—such as glucose meters, test strips, and lancets—and Continuous Glucose Monitoring (CGM) systems, which offer real-time glucose data through wearable sensors and transmitters. The growing global prevalence of diabetes, driven by sedentary lifestyles, obesity, and aging populations, remains a primary factor fueling market growth.
According to Fortune Business Insights, the blood glucose monitoring system market share was valued at USD 17.20 billion in 2024 and is projected to grow from USD 18.03 billion in 2025 to USD 27.73 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period. North America dominated the market, accounting for a 44.01% share in 2024.
The Blood Glucose Monitoring System Market report provides a comprehensive assessment of current trends, industry dynamics, market value, and future opportunities. It includes detailed analysis across product types, applications, patient care settings, and regions. The study also highlights technological innovations, clinical adoption rates, and regulatory updates shaping the industry’s future landscape.
Leading players operating in the global market include:
Abbott (U.S.)
Braun SE (Germany)
Dexcom, Inc. (U.S.)
Ascensia Diabetes Care Holdings AG (Switzerland)
Medtronic (Ireland)
Hoffmann-La Roche Ltd (Switzerland)
Terumo Corporation (Japan)
LifeScan IP Holdings, LLC (U.S.)
Senseonics (U.S.)
These companies are focusing on innovation, product approvals, and strategic collaborations to strengthen their global presence. Continuous glucose monitoring (CGM) technologies, smart sensors, and user-friendly devices are at the core of their development strategies.
Rising global prevalence of diabetes, particularly among aging populations, is driving the need for effective glucose management tools.
Technological advancements such as non-invasive glucose sensors, smartphone integration, and real-time data tracking have improved accuracy and patient convenience.
Growing preference for home-based monitoring devices, supported by telemedicine and digital health platforms.
Government initiatives to promote diabetes management and awareness, especially in developed countries.
High device costs and limited reimbursement in certain developing regions continue to limit adoption.
Technical errors and calibration issues in older-generation monitoring systems can affect patient compliance.
Lack of skilled professionals and insufficient awareness in low-income countries pose challenges to market expansion.
The market is moderately consolidated, with key players investing in product innovations, regulatory approvals, and partnerships. Companies are introducing continuous glucose monitoring systems with improved wear time, accuracy, and connectivity. In April 2025, Dexcom, Inc. received FDA approval for its Dexcom G7 15-Day CGM for adults over the age of 18 in the U.S., enhancing its brand visibility and market reach. Other players such as Abbott and Medtronic are also focusing on expanding product portfolios through next-generation glucose sensors and integrated insulin management platforms.
The market is segmented by device type, patient care setting, application, and testing site:
By Device Type: Self-Monitoring Blood Glucose (SMBG) Systems and Continuous Glucose Monitoring (CGM) Systems. The CGM segment dominates due to real-time monitoring and advanced analytics.
By Patient Care Setting: Home-care/self-care and hospitals & clinics. The home-care segment is expanding rapidly owing to convenience and patient independence.
By Application: Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Type 2 Diabetes accounts for the largest share due to higher global incidence.
By Testing Site: Fingertip testing and alternate site testing, with fingertip testing remaining dominant due to accuracy and familiarity among users.
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/blood-glucose-monitoring-market-100648
North America dominated the global market with a share of 44.01% in 2024. The region’s growth is supported by high diabetes prevalence, strong presence of leading manufacturers, favorable reimbursement structures, and rapid adoption of smart health technologies. The U.S. holds the largest share within the region.
Europe remains a key market driven by early adoption of digital health tools, supportive government policies, and increasing elderly population. Countries like Germany, the U.K., and France are leading contributors.
Asia Pacific is projected to record the fastest growth rate through 2032, supported by rising diabetes incidence, growing healthcare infrastructure, and awareness programs across China, India, and Japan.
Rest of the World regions, including Latin America and the Middle East, are showing promising growth trends with increasing healthcare expenditure and awareness about diabetes management.
The future of the Blood Glucose Monitoring System Market looks promising with continuous innovations and integration of artificial intelligence (AI) and cloud-based monitoring systems. Increasing adoption of digital therapeutics and wearable technology is expected to revolutionize diabetes management. Emerging markets are likely to play a crucial role in expanding the industry’s footprint due to growing healthcare access and patient education.
Manufacturers are focusing on non-invasive devices, improved accuracy, and longer sensor lifespans to enhance patient experience. Strategic partnerships between device makers, hospitals, and telehealth platforms will further accelerate growth. The shift toward preventive healthcare and personalized medicine is expected to sustain market expansion beyond 2032.
In conclusion, the global Blood Glucose Monitoring System Market is poised for substantial growth over the coming years, driven by the increasing prevalence of diabetes, advancements in monitoring technologies, and rising patient awareness. While challenges such as high costs and limited reimbursement persist, ongoing innovation and digital transformation are expected to redefine glucose management. Major players like Abbott, Dexcom, and Medtronic continue to lead the market through product innovation, expanding access, and strategic collaborations. The growing demand for user-friendly, accurate, and connected glucose monitoring systems is set to shape the future of global diabetes care through 2032 and beyond.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com